Georgia Capital Plc
50.00
EUR
-1.50
(-2.91%)
Georgia Capital Plc
GETTEX:2IX
(Gettex)
Recent
price
50.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
GEL
•
in mil. unless spec.Working Capital
GEL
•
in mil. unless spec.Growth Rates
GEL
•
in mil. unless spec.Quarterly Revenue
GEL
•
in mil. unless spec.Quarterly Earnings Per Share
GEL
•
in mil. unless spec.Quarterly Dividends Per Share
GEL
•
in mil. unless spec.- Similar Companies
- Business
- Georgia Capital PLC is a UK-listed holding company that invests in and develops businesses primarily in Georgia, focusing on capital-light opportunities with potential to reach at least GEL 300 million equity value over 3-5 years before monetization through exits such as IPOs or trade sales. The company, founded in 2017 following its demerger from BGEO Group PLC and headquartered at 8a Petre Melikishvili Street in Tbilisi, Georgia, with a registered office at 51 Lime Street in London, manages a diversified portfolio of portfolio companies including a pharmacy retail business operating under brands GPC and Pharma Depot with franchises like The Body Shop and Alana Fleur Optics; a healthcare services segment encompassing hospitals, clinics, and diagnostics with recent expansions into arthroscopy, sports medicine, gynecology, and interventional cardiology; a property and casualty (P&C) and medical insurance business under brands Imedi L and Ardi; and significant stakes in water utilities (through GGU) and renewable energy, alongside prior holdings in wine and beer production (Teliani) and other sectors like automotive retail and education services. Georgia Capital operates mainly in Georgia with some pharmacy presence in Armenia and Azerbaijan, targeting institutional growth in sectors benefiting from the country's economic diversification and European integration, and maintains board positions in public portfolio companies while raising capital through equity, debt markets, and share buybacks. Recent developments include the completion of a water utility stake sale for $70.4 million in July 2025 following exercise of a put option; a binding agreement to acquire GORMED, a regional healthcare network with three clinics serving 80,000 patients across central Georgia including entry into Gori at under 4x 2026 EBITDA; ongoing share buybacks totaling 15.2 million shares for $221 million through Q3 2025 with an additional US$50 million programme commenced in August 2025 and US$25 million increase in March 2025; a GEL 350 million bond issuance by the healthcare services business in September 2025; renewal of CEO Irakli Gilauri's contract in November 2025; launch of new digital solutions and brand identities in health insurance; network expansion by eight pharmacies in Q3 2025; and redemption of US$100 million local bonds in September 2025.
Company News
Georgia Capital PLC (GRGCF) Q2 2026 Earnings Call Transcript
Georgia Capital H1 Earnings Call Highlights
Georgia Capital PLC (GRGCF) Q1 2026 Earnings Call Transcript
Georgia Capital PLC (GRGCF) Q3 2025 Earnings Call Transcript